Analysis for RVTY

📈 Growth & Financial Trajectory

Through 7 completed quarters, revenue rose from $684.0M (2024 Q3) to $729.7M (2027 Q2), a modest ~6-7% expansion. Net income declined from $93.4M to $51.8M, implying a tilt toward lower profitability despite top-line growth. Quarter-to-quarter swings in operating income and cash flow reflect ongoing investment and cost dynamics, with operating cash flow remaining positive but variable.

💰 Margins & Cash Flow

Gross margin has trended in the mid‑50s percent range, recent quarters around 57%; operating margin has generally been in the low double digits, reflecting steady operating leverage. Net cash flow from operating activities has been positive in multiple periods (e.g., roughly $134M in 2025 Q2 and $182M in 2025 Q4) and remained meaningful in 2027 Q2 ($115M), while investing and financing outflows produced negative overall cash flow in the latest period.

🛡️ Balance Sheet & Liquidity

Assets run near $12.0B with equity around $7.2–7.6B and liabilities near $4.8B, indicating solid balance-sheet resilience. Current assets exceed current liabilities in aggregate, supporting liquidity for ongoing R&D and capex; long‑term liabilities exist but are manageable relative to equity.

⚠️ Key Drivers & Risks

• Drivers: biotech/life-science R&D demand; adoption of Revvity’s instruments and reagents.
• Risks: cyclicality in research funding and revenue, high R&D/intangible asset intensity, and sensitivity to profitability and financing mix.